Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

We are pleased to announce The Max Foundation CEO and co-founder, Pat Garcia-Gonzalez, has been nominated as one of three finalists for the Outstanding Contribution to Cancer Control Award, by UICC. We are honored to see The Max Foundation’s efforts recognized by the UICC.

Pat Garcia-Gonzalez shared her gratitude, saying, “This nomination means the world to me and to all whose voices we represent. At The Max Foundation we believe that all people should be able to access the treatment they need, geography should not be destiny, and everyone should be able to strive for health with dignity and hope.

In the past 20 years we have demonstrated that it is possible to safely treat many cancers in low- and middle-income countries. Now we can prevent unnecessary suffering and premature death and because we can, we must.”

Pat is nominated in the civil society category, alongside Paul Farmer, Co-Founder and Chief Strategist, Partners in Health, and Maira Caleffi, breast surgeon and founder of FEMAMA. UICC has also nominated President Joe Biden, Minister Greg Hunt, and President Paul Kagame in the policy-makers category.

The panel of judges for UICC’s Outstanding Contribution to Cancer Control Awards includes: the members of the Board of the Union for International Cancer Control (UICC); the Editors in Chief of the three following scientific journals: Lancet Oncology, International Journal of Cancer, Journal of Global Oncology; and the CEO of the American Society for Clinical Pathology.

The Awards Ceremony will take place October 26th at the 2021 World Cancer Leaders’ Summit in Boston.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….

  • The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low and middle income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.

  • Solidarity Fund Celebrates First Delivery

    Solidarity Fund Celebrates First Delivery

    Earlier this month, The Max Foundation celebrated the delivery of 110 BCR-ABL molecular tests to Mercy Medical Center Cambodia. The delivery was the first of its kind for Max, made possible through our 2018 Diagnostics Solidarity Fund. Two more deliveries – one to Kyrgyzstan and one to Bolivia – are in process now, and we’re hopeful there will be many more to come.